Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics completes BLA submission for nomlabofusp in Friedreich's ataxia

Positive Impact 4 of 5 legal/regulatory

Larimar Therapeutics said it completed its rolling Biologics License Application with the FDA, seeking accelerated approval of nomlabofusp for Friedreich's ataxia. The company also disclosed a preliminary, unaudited $128.7 million in cash, cash equivalents and marketable securities as of September 30, 2026, with its quarter-end close not yet complete, so shareholders should note that figure could change.

Key points

  • Rolling BLA submission to the FDA completed; the company seeks accelerated approval based on skin frataxin as a potential novel surrogate endpoint.
  • Preliminary cash, cash equivalents and marketable securities of approximately $128.7 million as of September 30, 2026, subject to change after financial statement closing procedures.
  • The updated corporate deck projects cash runway into late Q2 2027 and lists BLA acceptance for early 2027 and U.S. approval for mid-2027 as estimated timing.

The filing

CompanyLarimar Therapeutics, Inc. (LRMR)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:08 PM ET
Accession number0001193125-26-453586

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 6:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.